SOURCE: AtheroGenics, Inc.

August 29, 2006 08:14 ET

AtheroGenics to Present at Thomas Weisel Partners' Healthcare Conference on September 6, 2006

ATLANTA, GA -- (MARKET WIRE) -- August 29, 2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a company overview and update at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 6, 2006, at 1:30 p.m. EDT at The Four Seasons Hotel in Boston, Massachusetts.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations website at A replay of the presentation will be available on the Company's website for 30 days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit

Contact Information

    Corporate Communications
    Donna L. Glasky
    AtheroGenics, Inc.
    Email Contact

    Media Inquiries
    Jayme Maniatis
    Schwartz Communications, Inc.
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    Email Contact